Psychostimulants in Attention Deficit Hyperactivity Disorder: Theoretical and Practical Issues for the Community Practitioner

Contemporary Clinical Neuroscience

Volumn , Issue , 2005, Pages 487-527

  Connor, Daniel F ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

Acad Child Adolesc Psychiatry; Mixed Amphetamine Salt; Stimulant Medication; Stimulant Therapy; Stimulant Treatment

Indexed keywords

EID: 85145682483     PISSN: 2627535X     EISSN: 26275341     Source Type: Book Series    
DOI: 10.1385/1-59259-891-9:487     Document Type: Chapter

References (230)

1. Pliszka SR. Neuroscience for the mental health clinician. New York: Guilford Press, 2003;279.
2. Spencer T, Biederman J, Wilens T, Harding M, O’Donnell D, Griffin S. Pharmacotherapy of attention-deficit hyperactivity disorder across the life cycle. J Am Acad Child Adolesc Psychiatry 1996;35:409–432.
3. Barkley RA, DuPaul GJ, Connor DF. Stimulants. In: Werry JS, Aman MG, eds. Practitioner’s guide to psychoactive drugs for children and adolescents. New York: Plenum Medical Book Company, 1999;213–247.
4. Spencer T, Biederman J, Wilens T. Attention-deficit/hyperactivity disorder and comorbidity. Pediatr Clin North Am 1999;46:915–927.
5. Pliszka SR, Carlson CL, Swanson JM. ADHD with comorbid disorders: clinical assessment and management. New York: Guilford Press, 1999.
6. Barkley RA, Murphy KR. Attention deficit hyperactivity disorder: a clinical workbook. New York: Guilford Press, 1998;133.
7. Hechtman L, Weiss G, Perlman T. Young adult outcome of hyperactive children who received long-term stimulant treatment. J Am Acad Child Adolesc Psychiatry 1984;23:261–269.
8. Mannuzza S, Gittleman-Klein R, Bessler A, Malloy P, LaPadula M. Young adult outcome of hyperactive boys almost grown up: Educational achievement, occupational rank, and psychiatric status. Arch Gen Psychiatry 1993;50:565–576.
9. Faraone SV, Biederman J, Spencer T, et al. Attention-deficit/hyperactivity disorder in adults: an overview. Biol Psychiatry 2000;48:9–20.
10. Barkley RA. Attention-deficit hyperactivity disorder. Sci Am 1998;279:66–71.
11. Multimodal Treatment of ADHD Group. Moderators and mediators of treatment response for children with attention-deficit/hyperactivity disorder: the Multimodal Treatment Study of children with attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 1999;56:1088–1096.
12. Connor DF. Preschool attention deficit hyperactivity disorder: A review of prevalence, diagnosis, neurobiology, and stimulant treatment. Dev Behav Pediatrics 2002;23:S1–S9.
13. Pearson DA, Santos CW, Roache JD, et al. Treatment effects of methylphenidate on behavioral adjustment in children with mental retardation and ADHD. J Am Acad Child Adolesc Psychiatry 2003;42:209–216.
14. Handen BL, Breaux AM, Janosky J, McAuliffe S, Feldman H, Gosling A. Effects and noneffects of methylphenidate in children with mental retardation and ADHD. J Am Acad Child Adolesc Psychiatry 1992;31:455–461.
15. Aman MG, Marks RE, Turbott SH, Wilsher CP, Merry SN. Clinical effects of methylphenidate and thioridazine in intellectually subaverage children. J Am Acad Child Adolesc Psychiatry 1991;30:246–256.
16. Handen BL, Johnson CR, Lubetsky M. Efficacy of methylphenidate among children with autism and symptoms of attention-deficit hyperactivity disorder. J Autism Dev Dis 2000;30:245–255.
17. Mahalick DM, Carmel PW, Greenberg JP, et al. Psychopharmacologic treatment of acquired attention disorders in children with brain injury. Pediatr Neurosurg 1998;29:121–126.
18. Feldman H, Crumrine P, Handen R, Alvin R, Teodori J. Methylphenidate in children with seizures and attention-deficit disorder. Am J Dis Child 1989;143:1081–1086.
19. McBride MC, Wang DD, Torres CF. Methylphenidate in therapeutic doses does not lower seizure threshold. Ann Neurol 1986;20:428.
20. Hemmer SA, Pasternak JF, Zecker SG, Trommer BL. Stimulant therapy and seizure risk in children with ADHD. Pediatr Neurol 2001;24:99–102.
21. Weber P, Lutschg J. Methylphenidate treatment. Pediatr Neurol 2002;26:261–266.
22. Barkley RA. The effects of methylphenidate on the interactions of preschool ADHD children with their mothers. J Am Acad Child Adolesc Psychiatry 1988;27:336–341.
23. Zito JM, Safer DJ, dosReis S, et al. Psychotropic practice patterns for youth: a 10-year perspective. Arch Pediatr Adolesc Med 2003;157:17–25.
24. Zito JM, Safer DJ, dosReis S, Gardner JF, Boles M, Lynch F. Trends in the prescribing of psychotropic medications to preschoolers. JAMA 2000; 283:1025–1030.
25. Zito JM, Safer DJ, dosReis S, Magder LS, Gardner JF, Zarin DA. Psychotherapeutic medication patterns for youths with attention deficit/hyperactivity disorder. Arch Pediatr Adolesc Med 1999;153:1257–1263.
26. Willy ME, Manda B, Shatin D, Drinkard CR, Graham DJ. A study of compliance with FDA recommendations for pemoline (Cylert). J Am Acad Child Adolesc Psychiatry 2002;41:785–790.
27. Spencer T, Wilens T, Biederman J, Faraone SV, Ablon JS, Lapey K. A double-blind, crossover comparison of methylphenidate and placebo in adults with childhood-onset attention-deficit hyperactivity disorder. Arch Gen Psychiatry 1995;52:434–443.
28. Bhatara VS, Feil M, Hoagwood K, Vitiello B, Zima BT. Concomitant pharmacotherapy in youths receiving antidepressants or stimulants. Abstracts of Posters Presented at the 47th Annual Meeting of the American Academy of Child and Adolescent Psychiatry, Washington, DC, 2000.
29. Rushton JL, Whitmire JT. Pediatric stimulant and SSRI prescription trends: 1992–1998. Arch Pediatr Adolesc Med 2001;155:560–565.
30. Swanson JM, Connor D, Cantwell D. Combining methylphenidate and clonidine: Ill-advised. J Am Acad Child Adolesc Psychiatry 1999;38:617–619.
31. Safer DJ, Zito JM, Fine EM. Increased methylphenidate usage for attention deficit disorder in the 1990s. Pediatrics 1996;98:1084–1088.
32. Angold A, Erkanli A, Egger HL, Costello EJ. Stimulant treatment for children: a community perspective. J Am Acad Child Adolesc Psychiatry 2000;39:975–984.
33. Jensen P, Kettle L, Roper MT, et al. Are stimulants overprescribed? J Am Acad Child Adolesc Psychiatry 1999;38:797–804.
34. Jensen PS, Bhatara VS, Vitiello B, Hoagwood K, Feil M, Burke LB. Psychoactive medication prescribing practices for U.S. children: gaps between research and clinical practice. J Am Acad Child Adolesc Psychiatry 1999;38:557–565.
35. Wolraich ML, Lindgren S, Stromquist A, Milich R, Davis C, Watson D. Stimulant medication use by primary care physicians in the treatment of attention deficit hyperactivity disorder. Pediatrics 1990;86:95–101.
36. Cox ER, Motheral BR, Henderson RR, Mager D. Geographic variation in the prevalence of stimulant medication use among children 5 to 14 years old: Results from a commercially insured US sample. Pediatrics 2003;111:237–243.
37. Jensen PS. ADHD: Current concepts on etiology, pathophysiology, and neurobiology. Child Adolesc Psychiatr Clin N Am 2000;9:557–572.
38. Levy F. The dopamine theory of attention deficit hyperactivity disorder (ADHD). Aus N Zea J Psychiatry 1991;25:277–283.
39. Zametkin A, Liotta W. The neurobiology of attention-deficit/hyperactivity disorder. J Clin Psychiatry 1998;59:17–23.
40. Posner MI, Raichle ME. Images of mind (revised). Washington, DC: Scientific American Books, 1996.
41. Solanto MV. Neuropsychopharmacological mechanisms of stimulant drug action in attention-deficit hyperactivity disorder: a review and integration. Behav Brain Res 1998;94:127–152.
42. Faraone SV, Biederman J. Neurobiology of attention-deficit hyperactivity disorder. Biol Psychiatry 1998;44:951–958.
43. Volkow ND, Wang GJ, Fowler JS, et al. Relationship between blockade of dopamine transporters by oral methylphenidate and the increases in extracellular dopamine: Therapeutic implications. Synapse 2002;43:181–187.
44. Elia J, Borcherding B, Rapoport J, Keysor C. Methylphenidate and dextroamphetamine treatments of hyperactivity: are there true non-responders? Psychiatry Res 1991;36:141–155.
45. Greenhill LL, Abikoff H, Arnold LE, et al. Medication treatment strategies in the MTA study: relevance to clinicians and researchers. J Am Acad Child Adolesc Psychiatry 1996;35:1304–1313.
46. Wilens TE, Spencer TJ. The stimulants revisited. Child Adolesc Psychiatr Clin N Am 2000;9:573–603.
47. Pliszka SR, McCracken JT, Maas JW. Catecholamines in attention-deficit hyperactivity disorder: current perspectives. J Am Acad Child Adolesc Psychiatry 1996;35:264–272.
48. Diener RM. Toxicology of ritalin. In: Greenhill LL, Osman BB, eds. Ritalin theory and patient management. New York: Mary Ann Liebert, Inc., 1991:35–43.
49. Pelham WE, Jr., Sturges J, Hoza J, et al. Sustained release and standard methylphenidate effects on cognitive and social behavior in children with attention deficit disorder. Pediatrics 1987;80:491–501.
50. Pelham WE, Jr, Swanson JM, Furman MB, Schwindt H. Pemoline effects on children with ADHD: a time-response by dose-response analysis on classroom measures. J Am Acad Child Adolesc Psychiatry 1995;34:1504–1513.
51. Hoffman BB, Lefkowitz RJ. Catecholamines, sympathomimetic drugs, and adrenergic receptor antagonists. In: Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG, eds. The pharmacological basis of therapeutics. New York: McGraw-Hill, 1996:199–248.
52. Caldwell J, Sever PS. The biochemical pharmacology of abused drugs. Clin Pharmacol Ther 1974;16:625–638.
53. Greenhill LL. Attention deficit hyperactivity disorder: the stimulants. Child Adolesc Psychiatr Clin N Am 1995;4:123–168.
54. Birmaher B, Greenhill LL, Cooper TB, Fried J, Maminski B. Sustained release methylphenidate: pharmacokinetic studies in ADDH males. J Am Acad Child Adolesc Psychiatry 1989;28:768–772.
55. Ding YS, Fowler JS, Volkow ND, et al. Chiral drugs: Comparison of the pharmacokinetics of [11C]d-threo and l-threo-methylphenidate in the human and baboon brain. Psychopharmacol 1997;131:71–78.
56. Novartis Pharmaceuticals. Ritalin LA product monograph. East Hanover, NJ: Novartis Pharmaceuticals, 2002.
57. Pelham WE, Gnagy EM, Burrows-Maclean L, et al. Once-a-day Concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings. Pediatrics 2001;107:1–15.
58. Swanson JM, Gupta S, Guinta D, et al. Acute tolerance to methylphenidate in the treatment of attention deficit hyperactivity disorder in children. Clin Pharmacol Ther 1999; 66:295–305.
59. McNeil Pharmaceuticals. Concerta product monograph. 2001:2–28.
60. Grcevich S. SLI381: a long-acting psychostimulant preparation for the treatment of attention-deficit hyperactivity disorder. Expert Opin Investig Drugs 2001;10:2003–2011.
61. Michaels MA, Weston IE, Zhang Y, Tulloch SJ. Pharmacokinetics of SLI381, a two-component extended-release formulation of mixed amphetamine salts, administered in fasted and fed states, and sprinkled on food. New Drug Clinical Evaluation Unit, Phoenix, AZ, May 29, 2001.
62. Shire Pharmaceuticals. Adderall XR data on file. Shire US, Inc., 2001.
63. Greenhill LL, Pelham WE, Lopez FE, et al. Once-daily transdermal methylphenidate improves teacher, parent, and CGI-I ratings. 49th Annual Meeting of the American Academy of Child and Adolescent Psychiatry, San Francisco, CA, 2002.
64. Stahl SM. Mirror, mirror on the wall, which enantiomer is fairest of them all? J Clin Psychiatry 2002;63:656–657.
65. Eckerman DA, Moy SS, Perkins AN, Patrick KS, Breese GR. Enantioselective behavioral effects of threo-methylphenidate in rats. Pharmacol Biochem Behav 1991;40:875–880.
66. Novartis Pharmaceuticals. Focalin product monograph. 2002:5–19.
67. Barkley RA. A review of stimulant drug research with hyperactive children. J Child Psychol Psychiatry 1977;18:137–165.
68. Greenhill LL, Group AS. Efficacy and safety of OROS MPH in adolescents with ADHD. 49th Annual Meeting of the American Academy of Child and Adolescent Psychiatry, San Francisco, CA, 2002.
69. Wilens TE, Biederman J, Spencer TJ, Prince J. Pharmacotherapy of adult attention deficit/hyperactivity disorder: a review. J Clin Psychopharmacol 1995;15:270–279.
70. Elia J, Rapoport J. Ritalin versus dextroamphetamine in ADHD: both should be tried. In: Greenhill LL, Osman BB, eds. Ritalin: theory and patient management. New York: Mary Ann Liebert Publishers, 1991:69–74.
71. Varley CK. Effects of methylphenidate in adolescents with attention deficit disorder. J Am Acad Child Adolesc Psychiatry 1983;22:351–354.
72. Goldman L, Genel M, Bezman R, Slanetz PJ. Diagnosis and treatment of attention-deficit/hyperactivity disorder in children and adolescents. JAMA 1998;279:1100–1107.
73. Milberger S, Biederman J, Faraone SV, Chen L, Jones J. Further evidence of an association between attention-deficit/hyperactivity disorder and cigarette smoking. Findings from a high-risk sample of siblings. Am J Addict 1997;6:205–217.
74. Milberger S, Biederman J, Faraone SV, Chen L, Jones J. ADHD is associated with early initiation of cigarette smoking in children and adolescents. J Am Acad Child Adolesc Psychiatry 1997;36:37–44.
75. Barkley RA, Guevremont DC, Anastopoulos AD, DuPaul GJ, Shelton TL. Driving-related risks and outcomes of attention deficit hyperactivity disorder in adolescents and young adults: a 3-to 5-year follow-up survey. Pediatrics 1993;92:212–218.
76. Barkley RA, Murphy KR, Kwasnik D. Motor vehicle driving competencies and risks in teens and young adults with attention deficit hyperactivity disorder. Pediatrics 1996;98:1089–1095.
77. Milberger S, Biederman J, Faraone SV, Wilens T, Chu MP. Associations between ADHD and psychoactive substance use disorders. Findings from a longitudinal study of high-risk siblings of ADHD children. Am J Addict 1997;6:318–329.
78. O’Donnell D, Biederman J, Jones J, et al. Informativeness of child and parent reports on substance use disorders in a sample of ADHD probands, control probands, and their siblings. J Am Acad Child Adolesc Psychiatry 1998;37:752–758.
79. Murphy K, Barkley RA. Attention deficit hyperactivity disorder adults: comorbidities and adaptive impairments. Compr Psychiatry 1996;37:393–401.
80. Whalen CK, Henker B, Granger DA. Social judgment processes in hyperactive boys: effects of methylphenidate and comparisons with normal peers. J Abnorm Child Psychol 1990;18:297–316.
81. Swanson JM, Granger D, Kliewer W. Natural social behaviors in hyperactive children: dose effects of methylphenidate. J Consult Clin Psychol 1987;55:187–193.
82. Rapport MD, Stoner G, DuPaul GJ, et al. Attention deficit disorder and methylphenidate: A multilevel analysis of dose-response effects on children’s impulsivity across settings. J Am Acad Child Adolesc Psychiatry 1988;27:60–69.
83. Connor DF, Glatt SJ, Lopez ID, Jackson D, Melloni RH Jr. Psychopharmacology and aggression. I: A meta-analysis of stimulant effects on overt/covert aggression-related behaviors in ADHD. J Am Acad Child Adolesc Psychiatry 2002;41:253–261.
84. Klein RG, Abikoff H, Klass E, Ganeles D, Seese LM, Pollack S. Clinical efficacy of methylphenidate in conduct disorder with and without attention deficit hyperactivity disorder. Arch Gen Psychiatry 1997;54:1073–1080.
85. Rapport MD, Kelly KL. Psychostimulant effects on learning and cognitive function in children with attention deficit hyperactivity disorder: Findings and implications. In: Matson JL, ed. Hyperactivity in children: a handbook. New York: Pergamon, 1991.
86. Rapport MD, Quinn SO, DuPaul GJ, et al. Attention deficit disorder with hyperactivity and methylphenidate: the effects of dose and mastery level on children’s learning performance. J Abnorm Child Psychol 1989;17:669–689.
87. Vyse SA, Rapport MD. The effects of methylphenidate on learning in children with ADDH: the stimulus-equivalence paradigm. J Consult Clin Psychol 1989;57:425–435.
88. Swanson JM, Kinsbourne M. The cognitive effects of stimulant drugs on hyperactive children. In: Hale GA, ed. Attention and cognitive development. New York: Plenum, 1978;249–274.
89. Bergman A, Winters L, Cornblatt B. Methylphenidate: effects on sustained attention. In: Greenhill LL, Osman BB, eds. Ritalin: theory and patient management. New York: Mary Ann Liebert, 1991;223–232.
90. Swanson JM. What do psychopharmacological studies tell us about information processing deficits in ADDH? In: Bloomingdale LM, Sergeant JA, eds. Attention deficit disorder: criteria, cognition, intervention. New York: Pergamon Press, 1988, pp. 97–116.
91. Sergeant JA, van der Meere J. Ritalin effects and information processing in hyperactivity. In: Greenhill LL, Osman BB, eds. Ritalin: theory and patient management. New York: Mary Ann Liebert, 1991, pp. 1–13.
92. Schachar R, Tannock R. Childhood hyperactivity and psychostimulants: a review of extended treatment studies. J Child Adolesc Psychopharmacol 1993:81–97.
93. Gillberg C, Melander H, von Knorring AL, et al. Long-term stimulant treatment of children with attention-deficit hyperactivity disorder symptoms. A randomized, double-blind, placebo-controlled trial. Arch Gen Psychiatry 1997;54:857–864.
94. Famularo R, Fenton T. The effect of methylphenidate on school grades in children with attention deficit disorder without hyperactivity: a preliminary study. J Clin Psychiatry 1987;48:112–114.
95. Rapport MD, Jones JT, DuPaul GJ, et. al. Attention deficit disorder and methylphenidate: group and single-subject analyses of dose effects on attention in clinic and classroom settings. J Clin Child Psychol 1987;16:329–338.
96. Barkley RA. The use of psychopharmacology to study reciprocal influences in parent-child interaction. J Abnorm Child Psychol 1981;9:303–310.
97. Barkley RA. Hyperactive girls and boys: stimulant drug effects on mother-child interactions. J Child Psychol Psychiatry 1989;30:379–390.
98. Whalen CK, Henker B, Dotemoto S. Methylphenidate and hyperactivity: Effects on teacher behaviors. Science 1980;208:1280–1282.
99. Barkley RA, Anastopoulos AD, Guevremont DC, Fletcher KE. Adolescents with attention deficit hyperactivity disorder: mother-adolescent interactions, family beliefs and conflicts, and maternal psychopathology. J Abnorm Child Psychol 1992;20:263–288.
100. Seidman LJ, Biederman J, Weber W, Hatch M, Faraone SV. Neuropsychological function in adults with attention-deficit hyperactivity disorder. Biol Psychiatry 1998;44:260–268.
101. Connor DF, Edwards G, Fletcher KE, Baird J, Barkley RA, Steingard RJ. Correlates of comorbid psychopathology in children with ADHD. J Am Acad Child Adolesc Psychiatry 2003;42:193–200.
102. Pisterman S, McGrath P, Firestone P, et al. Outcome of parent-mediated treatment of preschoolers with attention deficit disorder. J Consult Clin Psychol 1989;57:628–635.
103. Forehand R, McMahon RJ. Helping the noncompliant child: a clinician’s guide to parent training. New York: Guilford Press, 1981.
104. Handen BL, Feldman HM, Lurier A, et al. Efficacy of methylphenidate among preschool children with developmental disabilities and ADHD. J Am Acad Child Adolesc Psychiatry 1999;38:805–812.
105. Musten LM, Firestone P, Pisterman S, et al. Effects of methylphenidate on preschool children with ADHD: cognitive and behavioral functions. J Am Acad Child Adolesc Psychiatry 1997;36:1407–1415.
106. Firestone P, Monteiro-Musten L, Pisterman S, et. al. Short-term side effects of stimulant medication are increased in preschool children with attention-deficit/hyperactivity disorder: a double-blind placebo-controlled study. J Child Adolesc Psychopharmacol 1998;8:13–25.
107. Greenhill LL, Jensen P, Abikoff H, et al. Developing strategies for psychopharmacological studies in preschool children. J Am Acad Child Adolesc Psychiatry 2003;42:406–414.
108. Pelham WE, Vodde-Hamilton M, Murphy DA, Greenstein JJ, Vallano G. The effects of methylphenidate on ADHD adolescents in recreational, peer group, and classroom settings. J Clin Child Psychol 1991;20:293–300.
109. Smith BH, Pelham WE, Gnagy E, Yudell RS. Equivalent effects of stimulant treatment for attention-deficit hyperactivity disorder during childhood and adolescence. J Am Acad Child Adolesc Psychiatry 1998;37:314–321.
110. Coons HW, Klorman R, Borgstedt AD. Effects of methylphenidate on adolescents with a childhood history of attention deficit disorder: II. Information processing. J Am Acad Child Adolesc Psychiatry 1987;26:368–374.
111. Klorman R, Coons HW, Borgstedt AD. Effects of methylphenidate on adolescents with a childhood history of attention deficit disorder: I. Clinical findings. J Am Acad Child Adolesc Psychiatry 1987;26:363–367.
112. Evans SW, Pelham WE, Smith BH, et al. Dose-response effects of methylphenidate on ecologically valid measures of academic performance and classroom behavior in adolescents with ADHD. Exp Clin Psychopharmacol 2001;9:163–175.
113. Smith BH, Pelham WE, Evans S, et al. Dosage effects of methylphenidate on the social behavior of adolescents diagnosed with attention-deficit hyperactivity disorder. Exp Clin Psychopharmacol 19986:187–204.
114. Spencer T, Biederman J, Wilens TE, Faraone SV. Adults with attention-deficit/hyperactivity disorder: a controversial diagnosis. J Clin Psychiatry 1998;59:59–68.
115. Silver LB. Attention-deficit/hyperactivity disorder in adult life. Child Adolesc Psychiatr Clin N Am 2000;9:511–523.
116. Faraone SV, Biederman J, Mick E. Symptom reports by adults with attention deficit hyperactivity disorder: are they influenced by attention deficit hyperactivity disorder in their children? J Nerv Ment Dis 1997;185:583–584.
117. Fischer M, Barkley RA, Smallish L, Fletcher K. Young adult follow-up of hyperactive children: self-reported psychiatric disorders, comorbidity, and the role of childhood conduct problems and teen CD. J Abnorm Child Psychol 2002;30:463–475.
118. Wood DR, Reimherr FW, Wender PH, Johnson GE. Diagnosis and treatment of minimal brain dysfunction in adults. Arch Gen Psychiatry 1976;33:1453–1460.
119. Wender PH, Reimherr FW, Wood DR. Attention deficit disorder (minimal brain dysfunction) in adults. Arch Gen Psychiatry 1981;38:449–456.
120. Wender PH, Reimherr FW, Wood DR, Ward M. A controlled study of methylphenidate in the treatment of attention deficit disorder, residual type, in adults. Am J Psychiatry 1985;142:547–552.
121. Faraone SV, Biederman J, Chen WJ, Milberger S, Warburton R, Tsuang MT. Genetic heterogeneity in attention-deficit hyperactivity disorder (ADHD): gender, psychiatric comorbidity, and maternal ADHD. J Abnorm Psychol 1995;104:334–345.
122. Mattes JA, Boswell L, Oliver H. Methylphenidate effects on symptoms of attention deficit disorder in adults. Arch Gen Psychiatry 1984;41:1059–1063.
123. Brown TE. Attention-deficit disorders and comorbidities in children, adolescents, and adults. Washington, DC: American Psychiatric Press, 2000.
124. Biederman J, Newcorn J, Sprich S. Comorbidity of attention deficit hyperactivity disorder with conduct, depressive, anxiety, and other disorders. Am J Psychiatry 1991;148:564–577.
125. Biederman J, Faraone S, Spencer T, et al. Patterns of psychiatric comorbidity, cognition, and psychosocial functioning in adults with attention deficit/hyperactivity disorder. Am J Psychiatry 1993;150:1792–1798.
126. Szatmari P, Boyle M, Offord DR. ADDH and conduct disorder: degree of diagnostic overlap and differences among correlates. J Am Acad Child Adolesc Psychiatry 1989;28:865–872.
127. Barkley RA, McMurray MB, Edelbrock CS, Robbins K. The response of aggressive and nonag-gressive ADHD children to two doses of methylphenidate. J Am Acad Child Adolesc Psychiatry 1989;28:873–881.
128. Klorman R, Brumaghim JT, Salzman LF, et al. Effects of methylphenidate on attention-deficit hyperactivity disorder with and without aggressive/noncompliant features. J Abnorm Psychol 1988;97:413–422.
129. Spencer T, Wilens T, Biederman J, Wozniak J, Harding-Crawford M. Attention-deficit/hyperactivity disorder with mood disorders. In: Brown TE, ed. Attention deficit disorders and comorbidities in children, adolescents, and adults. Washington, DC: American Psychiatric Press, 2000:79–124.
130. Biederman J, Lapey KA, Milberger S, Faraone SV, Reed ED, Seidman LJ. Motor preference, major depression and psychosocial dysfunction among children with attention deficit hyperactivity disorder. J Psychiatr Res 1994;28:171–184.
131. Biederman J, Mick E, Faraone SV. Depression in attention deficit hyperactivity disorder (ADHD) children: “true” depression or demoralization? J Affect Disord 1998;47:113–122.
132. DuPaul GJ, Barkley RA, McMurray MB. Response of children with ADHD to methylphenidate: interaction with internalizing symptoms. J Am Acad Child Adolesc Psychiatry 1994;33:894–903.
133. Jensen P, Hinshaw SP, Swanson JM, et al. Findings from the NIMH multimodal treatment study of ADHD (MTA): implications and applications for primary care providers. J Dev Behav Pediatr 2001;22:60–73.
134. Gadow KD, Nolan EE, Sverd J, Sprafkin J, Schwartz J. Anxiety and depressive symptoms and response to methylphenidate in children with attention-deficit/hyperactivity disorder and tic disorder. J Clin Psychopharmacol 2002;22:267–274.
135. Findling RL. Open-label treatment of comorbid depression and attentional disorders with coadministration of serotonin reuptake inhibitors and psychostimulants in children, adolescents, and adults: a case series. J Child Adolesc Psychopharmacol 1996;6:165–175.
136. Gammon GD, Brown TE. Fluoxetine and methylphenidate in combination for treatment of attention deficit disorder and comorbid depressive disorder. J Child Adolesc Psychopharmacol 1991;3:1–10.
137. Geller B, Zimerman B, Williams M, DelBello MP, Frazier J, Beringer L. Phenomenology of prepubertal and early adolescent bipolar disorder: examples of elated mood, grandiose behaviors, decreased need for sleep, racing thoughts, and hypersexuality. J Child Adolesc Psychopharmacol 2002;12:3–9.
138. Geller B, Zimerman B, Williams M, et al. DSM-IV mania symptoms in a prepubertal and early adolescent bipolar disorder phenotype compared to attention-deficit hyperactive and normal controls. J Child Adolesc Psychopharmacol 2002;12:11–25.
139. Scheffer RE. Combination pharmacotherapy in pediatric bipolars-treating comorbid ADHD. Presented at the 49th Annual Meeting of the American Academy of Child and Adolescent Psychiatry, San Francisco, CA, October 2002;22–27.
140. Cohen P, Cohen J, Kasen S, et al. An epidemiological study of disorders in late childhood and adolescence: I. age and gender specific pattern. J Child Psychol Psychiatry 1993;34:851–867.
141. Bird HR, Gould MS, Staghezza BM. Patterns of diagnostic comorbidity in a community sample of children aged 9 through 16 years. J Am Acad Child Adolesc Psychiatry 1993;32:361–368.
142. Pliszka SR. Effect of anxiety on cognition, behavior, and stimulant response in ADHD. J Am Acad Child Adolesc Psychiatry 1989;28:882–887.
143. Buitelaar JK, van der Gaag RJ, Swaab-Barneveld H, et. al. Prediction of clinical response to methylphenidate in children with attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 1995;34:1025–1032.
144. Diamond IR, Tannock R, Schachar R. Response to methylphenidate in children with ADHD and comorbid anxiety. J Am Acad Child Adolesc Psychiatry 1999:402–409.
145. Research Units on Pediatric Psychopharmacology (RUPP) Group. Fluvoxamine for the treatment of anxiety disorders in children and adolescents. N Engl J Med 2001;344:1279–1285.
146. Kurlan R, Como PG, Miller B, et al. The behavioral spectrum of tic disorders: a community-based study. Neurology 2002;59:414–420.
147. Gadow KD, Nolan EE, Sprafkin J, Schwartz J. Tics and psychiatric comorbidity in children and adolescents. Dev Med Child Neurol 2002;44:330–338.
148. Snider LA, Seligman LD, Ketchen BR, et al. Tics and problem behaviors in school children: prevalence, characterization, and associations. Pediatrics 2002;110:331–336.
149. Sukhodolsky DG, Scahill L, Zhang H, et al. Disruptive behavior in children with Tourette’s syndrome: association with ADHD comorbidity, tic severity, and functional impairment. J Am Acad Child Adolesc Psychiatry 2003;41:98–105.
150. Pliszka SR. Comorbidity of attention-deficit/hyperactivity disorder with psychiatric disorder: an overview. J Clin Psychiatry 1998;59:50–58.
151. Castellanos FX, Giedd JN, Elia J, et al. Controlled stimulant treatment of ADHD and comorbid Tourette’s syndrome: effects of stimulants and dose. J Am Acad Child Adolesc Psychiatry 1997;36:1–8.
152. Gadow KD, Nolan EE, Sverd J. Methylphenidate in hyperactive boys with comorbid tic disorder: II. Short-term behavioral effect in school settings. J Am Acad Child Adolesc Psychiatry 1992;31:462–471.
153. Gadow KD, Nolan EE, Sverd J, Sprafkin J, Paolicelli L. Methylphenidate in aggressive-hyperac-tive boys: I. Effects on peer aggression in public school settings. J Am Acad Child Adolesc Psychiatry 1990;29:710–718.
154. Gadow KD, Sverd J, Sprafkin J, et al. Efficacy of methylphenidate for attention-deficit hyperactivity disorder in children with tic disorder. Arch Gen Psychiatry 1995;52:444–455.
155. Tourette’s Study Group. Treatment of ADHD in children with tics: a randomized controlled trial. Neurology 2002;58:527–536.
156. Riddle MA, Lynch KA, Scahill L, DeVries A, Cohen DJ, Leckman JF. Methylphenidate discontinuation and reinitiation during long-term treatment of children with Tourette’s disorder and attention-deficit hyperactivity disorder: a pilot study. J Child Adolesc Psychopharmacol 1995;3:191–205.
157. Scahill L, Chappell PB, Kim YS, et al. A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder. Am J Psychiatry 2001;158:1067–1074.
158. Purvis KL, Tannock R. Language abilities in children with attention deficit hyperactivity disorder, reading disabilities, and normal controls. J Abnorm Child Psychol 1997;25:133–144.
159. Murphy KR, Barkley RA, Bush T. Young adults with attention deficit hyperactivity disorder: subtype differences in comorbidity, educational, and clinical history. J Nerv Men Dis 2002;190:147–157.
160. Semrud-Clikeman M, Biederman J, Sprich-Buckminster S, Lehman BK, Faraone SV, Norman D. Comorbidity between ADDH and learning disability: a review and report in a clinically referred sample. J Am Acad Child Adolesc Psychiatry 1992;31:439–448.
161. Faraone SV, Biederman J, Lehman BK, et al. Evidence for the independent familial transmission of attention deficit hyperactivity disorder and learning disabilities: results from a family genetic study. Am J Psychiatry 1993;150:891–895.
162. Citizens Commission on Human Rights (CCHR). Ritalin: a warning to parents. Los Angeles, CA: Church of Scientology, 1987.
163. Volkow ND, Ding YS, Fowler JS, et al. Is methylphenidate like cocaine? Studies on their pharmacokinetics and distribution in the human brain. Arch Gen Psychiatry 1995;52:456–463.
164. Robinson TE, Berridge KC. The neural basis of drug craving: an incentive-sensitization theory of addiction. Brain Behav Rev 1993; 18:247–291.
165. Barkley RA, Fischer M, Smallish L, Fletcher K. Does the treatment of attention-deficit/hyperactivity disorder with stimulants contribute to drug use/abuse? A 13-year prospective study. Pediatrics 2003;111:97–109.
166. Wilens TE, Faraone SV, Biederman J, Gunawardene S. Does stimulant therapy of attention-deficit/hyperactivity disorder begat later substance abuse? A meta-analytic review of the literature. Pediatrics 2003;111:179–185.
167. Lambert NM, Hartsough CS. Prospective study of tobacco smoking and substance dependencies among samples of ADHD and non-ADHD participants. J Learn Disabil 1998;31:533–544.
168. Biederman J, Wilens T, Mick E, et al. Is ADHD a risk factor for psychoactive substance use disorders? Findings from a four-year prospective follow-up study. J Am Acad Child Adolesc Psychiatry 1997;36:21–29.
169. Biederman J, Wilens T, Mick E, Spencer T, Faraone SV. Pharmacotherapy of attention-deficit/hyperactivity disorder reduces risk for substance use disorder. Pediatrics 1999;104:e20.
170. Michelson D, Faries D, Wernicke J, et al. Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics 2001;108:e83.
171. Riggs PD. Clinical approach to treatment of ADHD in adolescents with substance use disorders and conduct disorder. J Am Acad Child Adolesc Psychiatry 1998;37:331–332.
172. Schachar RJ, Tannock R, Cunningham CE, Corkum PV. Behavioral, situational, and temporal effects of treatment of ADHD with methylphenidate. J Am Acad Child Adolesc Psychiatry 1997;36:754–763.
173. Wilens T, Pelham WE, Stein MT, et al. ADHD treatment with once-daily OROS methylphenidate: interim 12-month results from a long-term open-label study. J Am Acad Child Adolesc Psychiatry 2003;42:424–433.
174. Barkley RA, McMurray MB, Edelbrock CS, Robbins K. Side effects of methylphenidate in children with attention deficit hyperactivity disorder: a systemic, placebo-controlled evaluation. Pediatrics 1990;86:184–192.
175. Rapport MD, Moffitt C. Attention deficit/hyperactivity disorder and methylphenidate. A review of height/weight, cardiovascular, and somatic complaint side effects. Clin Psychol Rev 2002;22:1107–1131.
176. Brown RT, Wynne ME, Slimmer LW. Attention deficit disorder and the effect of methylphenidate on attention, behavioral, and cardiovascular functioning. J Clin Psychiatry 1984;45:473–476.
177. Rapoport J, Buchsbaum MS, Zahn TP, et al. Dextroamphetamine: cognitive and behavioral effects in normal prepubertal boys. Science 1978;199:560–562.
178. Johnston C, Pelham WE, Hoza J, et al. Psychostimulant rebound in attention deficit disordered boys. J Am Acad Child Adolesc Psychiatry 1988;27:806–810.
179. Denckla MB, Bemporad JR, MacKay MC. Tics following methylphenidate administration: a report of 20 cases. JAMA 1976;235:1349–1351.
180. Bremness AB, Sverd J. Methylphenidate-induced Tourette syndrome: case report. Am J Psychiatry 1979;136:1334–1335.
181. Lipkin P, Goldstein I, Adesman A. Tics and dyskinesias associated with stimulant treatment in attention-deficit hyperactivity disorder. Arch Pediatr Adolesc Med 1994;148:859–861.
182. Shapiro AK, Shapiro E. Do stimulants provoke, cause, or exacerbate tics and Tourette syndrome? Compr Psychiatry 1981;22:265–273.
183. Law SF, Schachar R. Do typical clinical doses of methylphenidate cause tics in children treated for attention-deficit hyperactivity disorder? J Am Acad Child Adolesc Psychiatry 1999;38:44–51.
184. Koehler-Troy C, Strober M, Malenbaum R. Methylphenidate induced mania in a prepubertal child. J Clin Psychiatry 1986;47:566–567.
185. Bloom AS, L.J. R, Weisskopf B, et al. Methylphenidate-induced delusional disorder in a child with attention deficit disorder with hyperactivity. J Am Acad Child Adolesc Psychiatry 1988;27:88–89.
186. Safer DJ, Allen R, Barr E. Depression of growth in hyperactive children on stimulant drugs. N Engl J Med 1972;287:217–220.
187. Gross M. Growth of hyperkinetic children taking methylphenidate, dextroamphetamine, or imipramine/desipramine. Pediatrics 1976;58:423–431.
188. Satterfield JH, Cantwell DP, Schell A, et al. Growth of hyperactive children treated with methylphenidate. Arch Gen Psychiatry 1979;36:212–217.
189. Spencer TJ, Biederman J, Harding M, O’Donnell D, Faraone SV, Wilens TE. Growth deficits in ADHD children revisited: evidence for disorder-associated growth delays? J Am Acad Child Adolesc Psychiatry 1996;35:1460–1469.
190. Gittelman R, Mannuzza S. Hyperactive boys almost grown up: III. Methylphenidate effects on ultimate height. Arch Gen Psychiatry 1988;45:1131–1134.
191. Klein RG, Mannuzza S. Hyperactive boys almost grown up: III. Methylphenidate effects on ultimate height. Arch Gen Psychiatry 1988;45:1131–1134.
192. Biederman J, Faraone SV, Mick E, et al. High risk for attention deficit hyperactivity disorder among children of parents with childhood onset of the disorder: a pilot study. Am J Psychiatry 1995;152:431–435.
193. Biederman J. Attention-deficit/hyperactivity disorder: a life-span perspective. J Clin Psychiatry 1998;59:4–16.
194. Biederman J, Faraone S, Milberger S, et al. A prospective 4-year follow-up study of attention-deficit hyperactivity and related disorders. Arch Gen Psychiatry 1996;53:437–446.
195. Faraone SV, Biederman J, Mennin D, Gershon J, Tsuang MT. A prospective four-year follow-up study of children at risk for ADHD: psychiatric, neuropsychological, and psychosocial outcome. J Am Acad Child Adolesc Psychiatry 1996;35:1449–1459.
196. Fischer M, Barkley RA, Edelbrock CS, Smallish L. The adolescent outcome of hyperactive children diagnosed by research criteria: II. Academic, attentional, and neuropsychological status. J Consult Clin Psychol 1990;58:580–588.
197. Fischer M, Barkley RA, Fletcher KE, Smallish L. The stability of dimensions of behavior in ADHD and normal children over an 8-year follow-up. J Abnorm Child Psychol 1993;21:315–337.
198. Mannuzza S, Klein RG, Addalli KA. Young adult mental status of hyperactive boys and their brothers: a prospective follow-up study. J Am Acad Child Adolesc Psychiatry 1991;30:743–751.
199. Fischer M, Barkley RA, Fletcher KE, Smallish L. The adolescent outcome of hyperactive children: predictors of psychiatric, academic, social, and emotional adjustment [see comments]. J Am Acad Child Adolesc Psychiatry 1993;32:324–332.
200. Barkley RA, DuPaul GJ, McMurray MB. Attention deficit disorder with and without hyperactivity: clinical response to three dose levels of methylphenidate. Pediatrics 1991;87:519–531.
201. Chatoor I, Wells KC, Conners CK, Seidel WT, Shaw D. The effects of nocturnally administered stimulant medication on EEG sleep and behavior in hyperactive children. J Am Acad Child Adolesc Psychiatry 1983;22:337–342.
202. Wilens TE, Biederman J, Prince J, et al. Six-week, double-blind, placebo-controlled study of desipramine for adult attention deficit hyperactivity disorder. Am J Psychiatry 1996;153:1147–1153.
203. Spencer T, Biederman J, Kerman K, Steingard R, Wilens T. Desipramine treatment of children with attention-deficit hyperactivity disorder and tic disorder or Tourette’s syndrome. J Am Acad Child Adolesc Psychiatry 1993;32:354–360.
204. Spencer T, Biederman J, Wilens T, Steingard R, Geist D. Nortriptyline treatment of children with attention-deficit hyperactivity disorder and tic disorder or Tourette’s syndrome. J Am Acad Child Adolesc Psychiatry 1993;32:205–210.
205. Klein-Schwartz W, McGrath J. Poison centers’ experience with methylphenidate abuse in preteens and adolescents. J Am Acad Child Adolesc Psychiatry 2003;42:288–294.
206. Rapport MD, Carlson GA, Kelly K, Pataki CS. Methylphenidate and desipramine in hospitalized children: I. Separate and combined effects on cognitive function. J Am Acad Child Adolesc Psychiatry 1993;32:333–342.
207. Pataki CS, Carlson GA, Kelly K, Rapport MD, Biancaniello T. Side effects of methylphenidate and desipramine alone and in combination in children. Am J Psychiatry 1993;32:1065–1072.
208. Prince JB, Wilens TE, Biederman J, Spencer TJ, Wozniak JR. Clonidine for sleep disturbances associated with attention-deficit hyperactivity disorder: a systematic chart review of 62 cases. J Am Acad Child Adolesc Psychiatry 1996;35:599–605.
209. Connor DF, Barkley RA, Davis HT. A pilot study of methylphenidate, clonidine, or the combination in ADHD comorbid with aggressive oppositional defiant or conduct disorder. Clin Pediatr (Phila) 2000;39:15–25.
210. Popper CW. Combining methylphenidate and clonidine: Pharmacologic questions and news reports about sudden death. J Child Adolesc Psychopharmacol 1995;5:157–166.
211. Fenichel RR. Combining methylphenidate and clonidine: the role of post-marketing surveillance. J Child Adolesc Psychopharmacol 1995;5:155–156.
212. Swanson JM, Flockhart D, Udrea D, Cantwell D, Connor D, Williams L. Clonidine in the treatment of ADHD: questions about safety and efficacy (letter). J Child Adolesc Psychopharmacol 1995;5:301–304.
213. Shevell M, Schreiber R. Pemoline-associated hepatic failure: A critical analysis of the literature. Pediatr Neurol 1997;16:14–16.
214. Klein RG. Pharmacotherapy of childhood hyperactivity: an update. In: Meltzer HY, ed. Psychopharmacology: the third generation of progress. New York: Raven Press, 1987:1215–1224.
215. Schleifer M, Weiss G, Cohen N, et al. Hyperactivity in preschoolers and the effect of methylphenidate. Am J Orthopsychiatry 1975;45:38–50.
216. Conners CK. Controlled trial of methylphenidate in preschool children with minimal brain dysfunction. Int J Ment Health 1975;4:61–74.
217. Cunningham CE, Siegel LS, Offord DR. A developmental dose-response analysis of the effects of methylphenidate on the peer interactions of attention deficit disordered boys. J Child Psychol Psychiatry 1985;26:955–971.
218. Barkley RA, Karlsson J, Strzelecki E, Murphy JV. Effects of age and Ritalin dosage on the mother-child interactions of hyperactive children. J Consult Clin Psychol 1984;52:750–758.
219. Mayes SD, Crites DL, Bixler EO, et al. Methylphenidate and ADHD: influence of age, IQ, and neurodevelopmental status. Dev Med Child Neurol 1994; 36:1099–1107.
220. Monteiro-Musten L, Firestone P, Pisterman S, et al. Effects of methylphenidate on preschool children with ADHD: cognitive and behavioral functions. J Am Acad Child Adolesc Psychiatry 1997;36:1407–1415.
221. Byrne JM, Bawden HN, DeWolfe NA, et al. Clinical assessment of psychopharmacological treatment of preschoolers with ADHD. J Clin Exp Neuropsychol 1998;20:613–627.
222. Brown RT, Sexson SB. A controlled trial of methylphenidate in black adolescents. Clin Pediatr 1987;27:74–81.
223. Barkley RA, Connor DF, Kwasnik D. Challenges to determining adolescent medication response in an outpatient clinical setting: Comparing Adderall and methylphenidate for ADHD. J Atten Dis 2000;4:102–113.
224. Bostic JQ, Biederman J, Spencer TJ, et al. Pemoline treatment of adolescents with attention deficit hyperactivity disorder: a short-term controlled trial. J Child Adolesc Psychopharmacol 2000;10:205–216.
225. Gualtieri CT, Ondrusek MG, Finley C. Attention deficit disorders in adults. Clin Neuropharmacol 1985;8:343–356.
226. Wilens TE, Biederman J, Spencer TJ, et al. Controlled trial of high doses of pemoline for adults with attention-deficit/hyperactivity disorder. J Clin Psychopharmacol 1999;19:257–264.
227. Paterson R, Douglas C, Hallmayer J, Hagan M, Krupenia Z. A randomized, double-blind, placebo-controlled trial of dexamphetamine in adults with attention deficit hyperactivity disorder. Aus NZ J Psychiatry 1999;33:494–502.
228. Schubiner H, Saules KK, Arfken CL, et al. Double-blind placebo-controlled trial of methylphenidate in the treatment of adult ADHD patients with comorbid cocaine dependence. Exp Clin Psychopharmacol 2002;10:286–294.
229. Greenhill LL, Findling RL, Swanson JM, et al. A double-blind, placebo-controlled study of mod-ified-release methylphenidate in children with attention-deficit/hyperactivity disorder. Pediatrics 2002;109:e39.
230. Biederman J, Lopez F, Boellner S, Chandler M. A randomized, double-blind, placebo-controlled, parallel-group study of SLI381 (Adderall XR) in children with attention-deficit/hyperactivity disorder. Pediatrics 2002;110:258–266.